▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1118 by analyst upside · 2026-09-28
QURE
uniQure N.V.
Healthcare · Market Cap $3B · P/E 0x
ANALYST PRICE TARGET
+78.6%
implied upside to consensus target
Current Price $38.23
Consensus Target $68.28
Bull Target $92.94
Bear Target $45.99
Analysts Covering 11
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
8
Hold
1
Sell
0
52-Week Low $8.73
52-Week High $71.5
YTD Return +63.4%
FUNDAMENTALS
Market Cap $3B
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-4.06
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $19M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $8.73
52-Week High $71.5
Current Price $38.23
Bear Target $45.99
Bull Target $92.94
● Now $38.23 ● Target $68.28
TRADING DATA
Avg Volume 1.4M
YTD Return +63.4%
Analyst Count 11
Consensus Buy
Upside to Target +78.6%
Last Updated 2026-09-28

ANALYST SUMMARY

uniQure N.V. (QURE) is currently trading at $38.23 with a Wall Street consensus price target of $68.28, implying potential upside of 78.6% over the next 12 months. 11 analysts currently cover QURE, with a consensus rating of Buy - 91% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $92.94, while the most cautious has a target of $45.99.

QURE operates in the Healthcare sector with a market capitalisation of $3B. The stock is up 63.4% year-to-date and is currently trading near the lower end of its 52-week range of $8.73 – $71.5.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for QURE, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Wells Fargo - Reiterated
Overweight → Overweight 2026-07-30 Building track record
Wolfe Research ↑ Upgrade
Peer Perform → Outperform 2026-07-30 Building track record
Barclays - Reiterated
Overweight → Overweight 2026-07-30 Building track record
HC Wainwright & Co. - Reiterated
Buy → Buy 2026-06-29 31% win rate (48 calls)
Mizuho - Reiterated
Outperform → Outperform 2026-06-25 Building track record
Barclays ↑ Upgrade
Equal-Weight → Overweight 2026-06-18 Building track record
Goldman Sachs - Reiterated
Neutral → Neutral 2026-06-18 Building track record
Leerink Partners - Reiterated
Outperform → Outperform 2026-06-18 29% win rate (7 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
46
out of 100
Coverage depth
19/30
Consensus clarity
5/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →